Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Frias JP, Nauck MA, Van J, et al. The Lancet 2018;392:2180-2193.
What it found
HbA1c fell by 1.06% to 1.94% depending on dose vs 0.06% with placebo and 1.21% with dulaglutide. Body weight changed by -0.9 kg to -11.3 kg vs -0.4 kg (placebo) and -2.7 kg (dulaglutide). Gastrointestinal events rose with dose, from 23.1% on 1 mg to 66.0% on 15 mg, vs 9.8% on placebo.
Limitations
Phase 2: about 50 people per arm and 26 weeks. Dose-finding study, not designed to judge long-term safety.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.